This NOF position paper provides evidence-based recommendations for preventing, diagnosing, and treating osteoporosis in postmenopausal women and men age 50 and older. It covers BMD testing indications, FRAX-based treatment thresholds derived from US cost-effectiveness modeling, and fracture risk reductions for all FDA-approved pharmacologic agents. It is the foundational clinical reference for osteoporosis management in orthopedic practice.
This NOF position paper provides evidence-based recommendations for preventing, diagnosing, and treating osteoporosis in postmenopausal women and men age 50 and older. It covers BMD testing indications, FRAX-based treatment thresholds derived from US cost-effectiveness modeling, and fracture risk reductions for all FDA-approved pharmacologic agents. It is the foundational clinical reference for osteoporosis management in orthopedic practice.